Literature DB >> 2727702

Catalytic hydrolysis of vasoactive intestinal peptide by human autoantibody.

S Paul1, D J Volle, C M Beach, D R Johnson, M J Powell, R J Massey.   

Abstract

Vasoactive intestinal peptide (VIP) labeled with 125I, [Tyr10-125I]VIP, can be hydrolyzed by immunoglobulin G (IgG) purified from a human subject, as judged by trichloroacetic acid precipitation and reversed-phase high-performance liquid chromatography (HPLC). The hydrolytic activity was precipitated by antibody to human IgG, it was bound by immobilized protein G and showed a molecular mass close to 150 kilodaltons by gel filtration chromatography, properties similar to those of authentic IgG. The Fab fragment, prepared from IgG by papain treatment, retained the VIP hydrolytic activity of the IgG. Peptide fragments produced by treatment of VIP with the antibody fraction were purified by reversed-phase HPLC and identified by fast atom bombardment-mass spectrometry and peptide sequencing. The scissile bond in VIP deduced from these experiments was Gln16-Met17. The antibody concentration (73.4 fmol per milligram of IgG) and the Kd (0.4 nM) were computed from analysis of VIP binding under conditions that did not result in peptide hydrolysis. Analysis of the antibody-mediated VIP hydrolysis at varying concentrations of substrate suggested conformity with Michaelis-Menton kinetics (Km). The values for Km (37.9 X 10(-9) M) and the turnover number kcat (15.6 min-1) suggested relatively tight VIP binding and a moderate catalytic efficiency of the antibody.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2727702     DOI: 10.1126/science.2727702

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  81 in total

Review 1.  Immunological origin and functional properties of catalytic autoantibodies to amyloid beta peptide.

Authors:  Sudhir Paul; Stephanie Planque; Yasuhiro Nishiyama
Journal:  J Clin Immunol       Date:  2010-05       Impact factor: 8.317

2.  Constitutive production of catalytic antibodies to a Staphylococcus aureus virulence factor and effect of infection.

Authors:  Eric L Brown; Yasuhiro Nishiyama; Jesse W Dunkle; Shreya Aggarwal; Stephanie Planque; Kenji Watanabe; Keri Csencsits-Smith; M Gabriela Bowden; Sheldon L Kaplan; Sudhir Paul
Journal:  J Biol Chem       Date:  2012-02-02       Impact factor: 5.157

Review 3.  Antibodies as defensive enzymes.

Authors:  Sudhir Paul; Yasuhiro Nishiyama; Stephanie Planque; Sangeeta Karle; Hiroaki Taguchi; Carl Hanson; Marc E Weksler
Journal:  Springer Semin Immunopathol       Date:  2005-01-05

4.  High levels of catalytic antibodies correlate with favorable outcome in sepsis.

Authors:  Sébastien Lacroix-Desmazes; Jagadeesh Bayry; Srini V Kaveri; David Hayon-Sonsino; Nithyananda Thorenoor; Julien Charpentier; Charles-Edouard Luyt; Jean-Paul Mira; Valakunja Nagaraja; Michel D Kazatchkine; Jean-François Dhainaut; Vincent O Mallet
Journal:  Proc Natl Acad Sci U S A       Date:  2005-03-02       Impact factor: 11.205

Review 5.  [Catalytic antibodies].

Authors:  D Baron
Journal:  Naturwissenschaften       Date:  1992-01

6.  The antiidiotypic approach to obtaining a proteolytic antibody.

Authors:  I V Smirnov; I I Vorobiev; A Friboulet; B Avalle; D Thomas; V D Knorre; A G Gabibov; N A Ponomarenko
Journal:  Dokl Biochem Biophys       Date:  2008 May-Jun       Impact factor: 0.788

7.  Antigen-specific proteolysis by hybrid antibodies containing promiscuous proteolytic light chains paired with an antigen-binding heavy chain.

Authors:  Gopal Sapparapu; Stephanie A Planque; Yasuhiro Nishiyama; Steven K Foung; Sudhir Paul
Journal:  J Biol Chem       Date:  2009-06-19       Impact factor: 5.157

8.  A human germ line antibody light chain with hydrolytic properties associated with multimerization status.

Authors:  Vikram Sharma; William Heriot; Kirk Trisler; Vaughn Smider
Journal:  J Biol Chem       Date:  2009-10-02       Impact factor: 5.157

Review 9.  Catalytic antibodies in healthy humans and patients with autoimmune and viral diseases.

Authors:  G A Nevinsky; Valentina N Buneva
Journal:  J Cell Mol Med       Date:  2003 Jul-Sep       Impact factor: 5.310

10.  VIP antagonists enhance excitatory cholinergic neurotransmission in the human airway.

Authors:  H Aizawa; H Inoue; M Shigyo; S Takata; H Koto; K Matsumoto; N Hara
Journal:  Lung       Date:  1994       Impact factor: 2.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.